HCC patient-voice themes¶

Last curated: 2026-08-30

Each theme below is supported by at least two retrieved sources. The synthesis is aggregate and paraphrased.

1. Physical symptoms and treatment effects overlap¶

Patients describe fatigue, appetite/weight changes, abdominal symptoms, sleep disruption, reduced activity, and treatment effects as one combined burden. The overlap makes it hard to know whether a change represents HCC, cirrhosis, or therapy (Patel 2022, PMID 34115280; Norman 2022, PMID 35974658).

Implication: outcome instruments and symptom triage should not assume a symptom belongs to one disease process.

2. Pervasive uncertainty structures the journey¶

Uncertainty extends from surveillance and indeterminate diagnosis through treatment response, recurrence, transplant waiting, and end-of-life decisions. It is a named cross-cutting theme in the qualitative review and appears longitudinally in patients navigating terminal HCC treatment (Norman 2022, PMID 35974658; Hansen 2015, PMID 25122134).

Implication: communication should state the next decision point and what evidence will resolve it, even when prognosis cannot be made certain.

3. Decisions are often clinician-led despite variable patient goals¶

International interviews found treatment decisions predominantly led by clinicians, while a later qualitative study directly examined how preferences enter multidisciplinary recommendations (Wörns 2024, PMID 39052152; Moon 2025, PMID 40453415).

Implication: eligibility should trigger a preference conversation, not close it.

Qualitative synthesis identifies social function and stigma as a core quality-of-life domain. Patients also report broad impacts on physical and role function that existing instruments incompletely capture (Norman 2022, PMID 35974658; Patel 2022, PMID 34115280).

Implication: HBV/HCV, alcohol, obesity, and transplant-deservingness narratives should be addressed without blame.

5. Caregivers feel unprepared and need symptom interpretation support¶

Caregivers near the end of life reported uncertainty, information needs, and difficulty distinguishing cirrhosis from HCC symptoms. Patients in the companion longitudinal study also described unmet information needs while navigating treatment (Hansen 2017, PMID 28820518; Hansen 2015, PMID 25122134).

Implication: caregiver education should include bleeding, encephalopathy, infection, and decompensation signals, with patient consent.

6. Transplant cure opens a new survivorship burden¶

Qualitative liver-transplant research identifies physical, emotional, psychological, and care-navigation challenges during early recovery, while recipients define survivorship around recurrence, quality of life, and competing health risks (Lieber 2022, PMID 34529886; Lieber 2021, PMID 33942480).

Boundary: these cohorts were not restricted to HCC and are indirect evidence for HCC transplant recipients.

7. Treatment burden is a preference-sensitive outcome¶

Japanese patients traded among features of TACE, hepatic arterial infusion, and oral treatment rather than choosing one route universally. REFLECT patient-reported outcomes show that treatment comparisons can differ in time to quality-of-life deterioration even when survival is the primary oncologic question (Chiba 2019, PMID 31118587; Vogel 2021, PMID 34087115).

Implication: administration, adverse effects, travel, and daily disruption belong in treatment comparisons.

8. Supportive and palliative care need begins before the last line¶

Terminal HCC interviews document symptom and decision burden over time, while a rapid review finds high need but a thin intervention evidence base for palliative care in decompensated cirrhosis/HCC (Hansen 2015, PMID 25122134; Mudumbi 2018, PMID 29698124).

Implication: lack of trial volume should not be mistaken for lack of supportive-care need.